EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment

Journal of Clinical Oncology

Volumn 23, Issue 4, 2005, Pages 857-865

  Marchetti, Antonio ^a   Martella, Carla ^a   Felicioni, Lara ^a   Barassi, Fabio ^a   Salvatore, Simona ^a   Chella, Antonio ^a   Camplese, Pier P ^a   Iarussi, Teodorico ^a   Mucilli, Felice ^a   Mezzetti, Andrea ^a   Cuccurullo, Franco ^a   Sacco, Rocco ^a   Buttitta, Fiamma ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; K RAS PROTEIN; PROTEIN TYROSINE KINASE INHIBITOR;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC PROCEDURE; EXON; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SMOKING; ADENOCARCINOMA; AGED; GENETICS; LUNG ALVEOLUS CELL CARCINOMA; LUNG TUMOR; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOCARCINOMA; ADENOCARCINOMA, BRONCHIOLO-ALVEOLAR; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 20044364933     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.043     Document Type: Article

References (46)

1. Cohen S: Purification of the receptor for epidermal growth factor from A-431 cells: Its function as a tyrosyl kinase. Methods Enzymol 99:379-387, 1983
2. Jorissen RN, Walker F, Pouliot N, et al: Epidermal growth factor receptor: Mechanisms of activation and signalling. Exp Cell Res 284:31-53, 2003
3. Wells A: Molecules in focus: EGF receptor. Int J Biochem Cell Biol 31:637-643, 1999
4. Cohen P: The role of protein phosphorylation in human health and disease: The Sir Hans Krebs Medal Lecture. Eur J Biochem 268:5001-5010, 2001
5. Huang HS, Nagane M, Klingbeil CK, et al: The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and un-attenuated signaling. J Biol Chem 272:2927-2935, 1997
6. Antonyak MA, Moscatello DK, Wong AJ: Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J Biol Chem 273:2817-2822, 1998
7. Blume-Jensen P, Hunter T: Oncogenic kinase signalling. Nature 411:355-365, 2001
8. Roskoski R Jr: The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319:1-11, 2004
9. Ciardiello F, De Vita F, Orditura M, et al: The role of EGFR inhibitors in nonsmall cell lung cancer. Curr Opin Oncol 16:130-135, 2004
10. Frederick L, Wang XY, Eley G, et al: Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. Cancer Res 60:1383-1387, 2000
11. Wong AJ, Ruppert JM, Bigner SH, et al: Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A 89:2965-2969, 1992
12. Lorimer IA: Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets 2:91-102, 2002
13. Levitzki A: EGF receptor as a therapeutic target. Lung Cancer 41:9-14, 2003
14. Hirsch FR, Scagliotti GV, Langer CJ, et al: Epidermal growth factor family of receptors in preneoplasia and lung cancer: Perspectives for targeted therapies. Lung Cancer 41:29-42, 2003
15. Brabender J, Danenberg KD, Metzger R, et al: Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 7:1850-1855, 2001
16. Rusch V, Klimstra D, Venkatraman E, et al: Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 3:515-522, 1997
17. Arteaga C: ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 284: 122-130, 2003
18. Rusch V, Baselga J, Cordon-Cardo C, et al: Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53:2379-2385, 1993
19. Ciardiello F, Tortora G: A novel approach in the treatment of cancer: Targeting the epidermal growth factor receptor. Clin Cancer Res 7:2958-2970, 2001
20. Ritter CA, Arteaga CL: The epidermal growth factor receptor-tyrosine kinase: A promising therapeutic target in solid tumors. Semin Oncol 30:3-11, 2003
21. Cohen MH, Williams GA, Sridhara R, et al: FDA drug approval summary: Gefitinib (ZD1839) Iressa) tablets. Oncologist 8:303-306, 2003
22. Green MR: Targeting targeted therapy. N Engl J Med 350:2191-2193, 2004
23. Cappuzzo F, Gregore V, Rossi E, et al: Gefitinib in pretreated non-small-cell lung cancer (NSCLC): Analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC. J Clin Oncol 21:2658-2663, 2003
24. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139, 2004
25. Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304:1497-1500, 2004
26. Smith MR, DeGudicibus SJ, Stacey DW: Requirement for c-ras proteins during viral oncogene transformation. Nature 320:540-543, 1986
27. Sobin LH, Witteking CH: TNM Classification of Malignant Tumours (ed 6). New York, NY, John Wiley & Sons Inc, 2002
28. Travis WD, Colby TV, Corrin B, et al: Histologic Typing of Tumours of Lung and Pleura: World Health Organization International Classification of Tumors (ed 3). New York, NY, Springer Verlag, 1999
29. Barkley JE, Green MR: Bronchioloalveolar carcinoma. J Clin Oncol 14:2377-2386, 1996
30. Marchetti A, Buttitta F, Merlo G, et al: p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res 53:2846-2851, 1993
31. Marchetti A, Buttitta F, Pellegrini S, et al: Bronchioloalveolar lung carcinomas: K-ras mutations are constant events in the mucinous subtype. J Pathol 179:254-259, 1996
32. Yano S, Kanematsu T, Miki T, et al: A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa"). Cancer Sci 94:453-458, 2003
33. Takao M, Inoue K, Watanabe F, et al: Successful treatment of persistent bronchorrhea by gefitinib in a case with recurrent bronchioloalveolar carcinoma: A case report. World J Surg Oncol 1:8, 2003
34. Miller VA, Kris MG, Shah N, et al: Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 22:1103-1109, 2004
35. Gandara DR, West H, Chansky K, et al: Bronchioloalveolar carcinoma: A model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res 10:4205-4209, 2004
36. Evans TL: Highlights from the Tenth World Conference on Lung Cancer. Oncologist 9:232-238, 2004
37. West H, Franklin WA, Gumerlock PH, et al: Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126. Proc Am Soc Clin Oncol 22:14s, 2004 (abstr 7014)
38. Sandler A: Clinical experience with the HER1/EGFR tyrosine kinase inhibitor erlotinib. Oncology (Huntingt) 17:17-22, 2003
39. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 101:13306-13311, 2004
40. Clayton F: The spectrum and significance of bronchioloalveolar carcinomas. Pathol Annu 23:361-394, 1988
41. Breathnach OS, Ishibe N, Williams J, et al: Clinical features of patients with stage IIIB and IV bronchioloalveolar carcinoma of the lung. Cancer 86:1165-1173, 1999
42. Marchetti A, Pellegrini S, Bertacca G, et al: FHIT and p53 gene abnormalities in bronchioloalveolar carcinomas: Correlations with clinicopathological data and K-ras mutations. J Pathol 184: 240-246, 1998
43. Marchetti A, Pellegrini S, Sozzi G, et al: Genetic analysis of lung tumours of non-smoking subjects: p53 gene mutations are constantly associated with loss of heterozygosity at the FHIT locus. Br J Cancer 78:73-78, 1998
44. Bosari S, Marchetti A, Buttitta F, et al: Detection of p53 mutations by single-strand conformation polymorphisms (SSCP) gel electrophoresis: A comparative study of radioactive and nonradioactive silver-stained SSCP analysis. Diagn Mol Pathol 4:249-255, 1995
45. Fan X, Furnari FB, Cavenee WK, et al: Non-isotopic silver-stained SSCP is more sensitive than automated direct sequencing for the detection of PTEN mutations in a mixture of DNA extracted from normal and tumor cells. Int J Oncol 18:1023-1026, 2001
46. Marchetti A, Merlo G, Buttitta F, et al: Detection of DNA mutations in acid formalin-fixed paraffin-embedded archival tumor specimens by polymerase chain reaction-single strand conformation polymorphism analysis. Cancer Detect Prev 19:278-281, 1995